+	Spec Heal	trum th	Physician's (FERRIC CAR (INJECTAFE ADULT, OUT INFUSION C Page 1 of 2	BOXYMALTOSE R) - TPATIENT,	Patient Name DOB MRN Physician FIN		
[Defaults for orde Interval: Even Interval: Even Interval: Even	ry 7 days ry 14 days	wise specified below ys	r.			
	Duration: 2 treatments Until date: 1 year# of T	reatments					
Antic	Anticipated Infusion Date ICD 10 Code with Description						
Heig	Height(cm) Weight(kg) Allergies						
□ Sł □ Sł	of Service H Gerber H Helen DeVos (GF		men Holton (GR) ngton	□ SH Pennock □ SH Reed City	□ SH United Memorial □ SH Zeeland		
□ AI □ Ca □ Ga	/ider Specialty lergy/Immunology ardiology astroenterology enetics		Med/Family Practice	□ OB/GYN □ Other □ Otolaryngology □ Pulmonary	 □ Rheumatology □ Surgery □ Urology □ Wound Care 		
+)	Status: Futu Infusion and	ppointment R re, Expected: S I possible labs	•	elerance: Schedule appointment at mo	st 3 days before or at most 3 days after,		
Prov	vider Ordering Gu	lidelines					
is required or permitted by law, regulation, or written authorization by the patient.	FERRIC CA Patients elig and/or iron s normal iron Prior to initia three times Dose of ferr For pa For pa	ible to receive for saturation less the studies may also ation of IV iron the the upper limit o ic carboxymaltors tients less than	SE (INJECTAFER): erric carboxymaltose infusio nan 20%; Patients may be o b be considered for iron the nerapy, patients should be e f normal, or patient receiving	considered with or without anemia, per apy. valuated for overt bleeding and poor o g hemodialysis.	fined as ferritin less than 100 mcg/mL sistently symptomatic patients with low lietary iron function tests greater than		
law, regulation, or		in + Hematoo	crit (H+H)	Interval Everydays Once 4 weeks post 2 nd infus Once	Duration Until date: sion 1 year# of Treatments		
ted by	Status: Futu	Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Collect, Blood, Blood, Venous					
uired or permit:	□ Ferritin, B	lood Level		 Everydays Once 4 weeks post 2nd infus Once 	Until date: sion 1 year# of Treatments	_	
is requ	Status: Futu	re, Expected: S,	Expires: S+365, URGENT,	Clinic Collect, Blood, Blood, Venous			

(+)

CONTINUED ON PAGE 2 →

Health

Spectrum FERRIC CARBOXYMALTOSE (INJECTAFER) -ADULT, OUTPATIENT, INFUSION CENTER (CONTINUED)

Patient Name
DOB
MRN
Physician

FIN Page 2 of 2 Labs (continued) Duration Interval Until date: Transferrin, Blood Level Everv days Once 4 weeks post 2nd infusion □ 1 year # of Treatments Once Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Collect, Blood, Blood, Venous Every _ Until date: Iron and Iron Binding Capacity Level davs □ Once 4 weeks post 2nd infusion 1 year # of Treatments Once Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Collect, Blood, Blood, Venous Additional Lab Orders Interval Duration Labs: Until date: Every days Once 1 year # of Treatments **Nursing Orders ONC NURSING COMMUNICATION 10** \checkmark FERRIC CARBOXYMALTOSE (INJECTAFER): Concerns related to adverse effects: • Hypersensitivity: Serious hypersensitivity reactions, including anaphylactic-type reactions (some life-threatening and fatal) have been reported. Monitor during and for at least 30 minutes after administration and until clinically stable. Signs/symptoms of serious hypersensitivity reaction include shock, hypotension, loss of consciousness, and/or collapse. Equipment for resuscitation, medication, and trained personnel experienced in handling emergencies should be immediately available during infusion. • Hypertension: Transient elevations in systolic blood pressure (sometimes with facial flushing, dizziness, or nausea) were observed in studies; usually occurred immediately after dosing and resolved within 30 minutes. Monitor blood pressure following infusion. Observe patient for signs and symptoms of hypersensitivity during and after ferric carboyxmaltose administration for at least 30 minutes and until clinically stable following completion of each administration. At the onset of any hypersensitivity reaction, the infusion must be stopped and the ordering physician or on-site nurse practitioner will be notified immediately with emergent medications given under that provider's direction. Patient may only be discharged if no signs or symptoms of hypertension or hypersensitivity reactions and the patient's vital signs are at baseline **ONC NURSING COMMUNICATION 100** \checkmark May Initiate IV Catheter Patency Adult Protocol Vitals Vital Signs \checkmark Routine, PRN, Starting S, Take vital signs at initiation and completion of infusion and as frequently as indicated by patient's symptoms Medications ferric carboxymaltose (INJECTAFER) in sodium chloride 0.9 % 50 mL IVPB \checkmark Dose: □ 750 mg □ 15 mg/kg (for patients less than 50 kg) Intravenous, for 15 Minutes, Once, Starting S, For 1 Dose Infuse over at least 15 minutes. Monitor for hypersensitivity reactions during and for at least 30 minutes after administration, and until clinically stable Telephone order/Verbal order documented and read-back completed. Practitioner's initials

NOTE: Unless Order is written DAW (dispense as written), medication may be supplied which is a generic equivalent by nonproprietary name.

TRANSCRIBED: VALIDATED: ORDERED: TIME DATE TIME DATE TIME DATE Pager # Sign R.N. Sign **Physician Print** Physician

X25239 (5/21) - Page 2 of 2 © Spectrum Health

+